4GS9
Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with an inactive benzoxadiazole antagonist
4GS9 の概要
エントリーDOI | 10.2210/pdb4gs9/pdb |
関連するPDBエントリー | 1P97 1X0O 2A24 2B02 3F1N 3F1O 3F1P 3H7W 3H82 4GHI |
分子名称 | Endothelial PAS domain-containing protein 1, Aryl hydrocarbon receptor nuclear translocator, N-(3-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine, ... (5 entities in total) |
機能のキーワード | pas fold, transcription, protein-protein interactions, nucleus |
由来する生物種 | Homo sapiens (human) 詳細 |
細胞内の位置 | Nucleus : Q99814 P27540 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 28426.04 |
構造登録者 | |
主引用文献 | Rogers, J.L.,Bayeh, L.,Scheuermann, T.H.,Longgood, J.,Key, J.,Naidoo, J.,Melito, L.,Shokri, C.,Frantz, D.E.,Bruick, R.K.,Gardner, K.H.,Macmillan, J.B.,Tambar, U.K. Development of Inhibitors of the PAS-B Domain of the HIF-2 alpha Transcription Factor J.Med.Chem., 56:1739-1747, 2013 Cited by PubMed Abstract: Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action. PubMed: 23363003DOI: 10.1021/jm301847z 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.72 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード